Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | ABBV | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 164.66 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 164.66 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 130.9601 - 182.89 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 164.66 | USD |
AbbVie (ABBV) Options Flow Summary
AbbVie Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 290.87B | 1.77B | - | 54.5B | 4.86B | 2.75 | 59.81 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AbbVie News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABBV Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 164.22 | 167.44 | 160.00 | 162.97 | 5,374,050 | 0.44 | 0.27% |
| 1 Month | 177.20 | 182.30 | 160.00 | 171.38 | 5,204,692 | -12.54 | -7.08% |
| 3 Months | 165.34 | 182.89 | 160.00 | 174.46 | 5,676,023 | -0.68 | -0.41% |
| 6 Months | 148.92 | 182.89 | 135.85 | 161.23 | 5,624,703 | 15.74 | 10.57% |
| 1 Year | 158.49 | 182.89 | 130.9601 | 153.29 | 5,400,158 | 6.17 | 3.89% |
| 3 Years | 108.26 | 182.89 | 105.56 | 141.83 | 6,090,943 | 56.40 | 52.10% |
| 5 Years | 77.60 | 182.89 | 62.55 | 114.65 | 7,157,027 | 87.06 | 112.19% |
AbbVie Description
| AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health. |
